Positron emission tomography in cancer research and treatment

Technology in Cancer Research and Treatment

Volumn 1, Issue 6, 2002, Pages 423-439

  Mandelkern, Mark ^a,b   Raines, Jonathan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 3 (2 FLUOROETHYL)SPIPERONE F 18; ACETIC ACID C 11; CAPROMAB PENDETIDE IN 111; CARBON 11; CHOLINE C 11; COPPER 62; COPPER 64; FLUORINE 18; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLCHOLINE F 18; GALLIUM 68; GERMANIUM; IODINE 124; IODINE 131; METHIONINE C 11; NITROGEN 13; NUCLEIC ACID; OXYGEN 15; PENTETREOTIDE IN 111; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82; SODIUM IODIDE; STRONTIUM 82; TECHNETIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

CANCER; CANCER CELL; CANCER RESEARCH; CELL PROLIFERATION; GLUCOSE METABOLISM; HUMAN; IMAGE QUALITY; IMAGING; METABOLISM; POSITRON EMISSION TOMOGRAPHY; RECEPTOR DENSITY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0038674360     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460200100603     Document Type: Review

References (97)

1. Levin, C. S., Hoffman, E. J. Calculation of positron range and its effect on the fundamental limit of positron emission tomography system spatial resolution. Phys. Med. Biol. 44, 781-799 (1999).
2. Mandelkern, M. Nuclear Techniques for Medical Imaging (PET). Annual Review of Nuclear and Particle Science 45, 205-254 (1995).
3. Derenzo, S. E. Precision measurement of annihilation point spread distributions for medically important positron emitters. Positron Annihilation ed. R. R. Hasiguti and K. Fujiwara (Sendai, Japan: The Japan Institute of Metals). 819-23 (1979).
4. Chatziioannou, A. F., Cherry, S. R., Shao, Y., Silverman, R. W., Meadors, K., Farquhar, T. H., Pedarsani, M., Phelps, M. E. Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J. Nucl. Med. 40, 1164-1175 (1999).
5. Nahmias, C., Nutt, R., Hichwa, R. D., Czernin, J., Melcher, C., Schmand, M., Efiksson, L., Andreaco, M., Casey, M., Moyers, C., Michel, C., Bruckbauer, T., Conti, M., Hamill, J., Bendriem, B. PET Tomograph Designed for Five Minute Routine Whole Body Studies. J. Nucl. Med. 43 (Suppl.), 11P (2002).
6. 18F-fluoride. Applied Radiation and Isotopes 55, 457-461 (2001).
7. Warburg, O., Posener, K., Negelein, E. VIII. The metabolism of cancer cells. Biochem. Zeitschr. 152, 129-169 (1924).
8. Hatanaka M. Transport of sugars in tumor cell membranes. Biochim. Biophys. Acta. 29, 77-104 (1974).
9. Birnbaum M., Haspel, H. C., Rosen, O. M. Transformation of Rat Fibroblasts by FSV Rapidly Increases Glucose Transporter Gene Transcription (in Reports). Science 235, 1495-1497 (1987).
10. Flier, J. S., Mueckler, M. M., Usher, P., Lodish, H. F. Elevated Levels of Glucose Transport and Transporter Messenger RNA are Induced by ras or src Oncogenes (in Reports). Science 235, 1492-1495 (1987).
11. Baldwin, S. A., Barros, L. F., Griffiths, M. Trafficking of glucose transporters-signals and mechanisms. Biosci. Rep. 15, 419-426 (1995).
12. Bell, G. I., Burant, C. F., Takeda, J., Gould, G. W. Structure and function of mammalian facilitative sugar transporters. J. Biol. Chem. 268, 19161-19164 (1993).
13. Su, T. S., Tsai, T. F., Chi, C. W., Han, S. H., Chou, C. K. Elevation of facilitated glucose-transporter messenger RNA in human hepatocellular carcinoma. Hepatology 11, 118-122 (1990).
14. Nishioka, T., Oda, Y., Seino, Y., Yamamoto, T., Inagaki, N., Yano, H., Imura, H., Shigemoto, R., Kikuchi, H. Distribution of the glucose transporters in human brain tumors. Cancer Res. 52, 3972-3979 (1992).
15. Sokoloff, L., Reivich, M., Kennedy, C., Des Rosiers, M. H., Patlak, C. S., Pettigrew, K. D., Sakurada, O., Shinohara, M. The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28, 897-916 (1977).
16. Stokkel, M. P., Bongers, V., Hordijk, G. J., van Rijk, P. P. FDG positron emission tomography in head and neck cancer: pitfall or pathology? Clin. Nucl. Med. 24, 950-41 (1999).
17. Mathews. D., Oz, O. K. Positron emission tomography in prostate and renal cell carcinoma. Curr. Opin. Urol. 12, 381-385 (2002).
18. Miraldi, F., Vesselle, H., Faulhaber, P. F., Adler L. P., Leisure G. P. Elimination of Artifactual Accumulatioof FDG in PET Imaging of Colorectal Cancer. Clin. Nuc. Med. 23, 3-7 (1998).
19. Kubota, K., Itoh, M. Ozaki, K., Ono, S., Tashiro, M., Yamaguchi, K, Akaizawa, T., Yamada. K., Fukuda, H. Advantage of delayed wholebody FDG-PET imaging for tumour detection. Eur. J. Nucl. Med. 28, 696-703 (2001).
20. Reske, S. N., Kotzerkej, J. FDG-PET for Clinical Use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", Eur. J. Nuc. Med. 23, 1641 (2000).
21. Gambhir, S. S., Czernin, J., Schwimmer, J., Silverman, D. H., Coleman, R. E., Phelps, M. E. A tabulated summary of the FDG PET literature. J. Nucl. Med. 42 (Suppl), 1S-93S (2001).
22. Delbeke D., Martin, W. H., Positron emission tomography imaging in oncology. Radiol. Clin. North. Am. 39, 883-917 (2001).
23. Hustinx, R., Smit, R. J., Benard, F., Bhatnagar, A., Alavi, A. occasional survey: Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur. J. Nuc. Med. 26, 1501-1509 (1999).
24. Di Chiro, G. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32, 1323-1329 (1982).
25. Delbeke, D., Meyerowitz, C., Lapidus, R. L., Maciunas, R. J., Jennings, M. T., Moots, P. L., Kessler, R. M. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195, 47-52 (1995).
26. Alavi, J. B., Alavi, A., Chawluk, J., Kushner, M., Powe, J., Hickey, W., Reivich, M. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62, 1074-1078 (1988).
27. Lonneux M., Lawson G., Ide C., Bausart R., Remacle M., Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 110, 1493-7 (2000).
28. Drazil, L., Mcnamee L. Head and neck cancer: Accuracy of electronic MRI co-registration with PET for detection of occult head & neck cancer. J. Nucl. Med. 43 (Suppl), 284P (2001).
29. Salman, K. T. K. Chacko, H. M. Zhuang, M. Hickeson, K. Z. Nakhoda, A. Alavi. Efficacy of FDG-PET in evaluating bronchioloalveolar carcinoma. J. Nucl. Med. 43 (Suppl.), 301P (2002).
30. Benard, F., Sterman, D., Smith, R. J., Kaiser, L. R., Albelda, S. M., Alavi, A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114, 713-22 (1998)
31. Schneider, D. B., Clary-Macy, C., Challa, S., Sasse, K. C., Merrick, S. H., Hawkins, R., Caputo, G., Jablons, D. Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 120, 128-33 (2000).
32. Yun, M., Kim, W., Alnafisi, N., Lacorte, L., Sunyoung Jang, S., Alavi, A. 18F-FDG PET in Characterizing Adrenal Lesions Detected on CT or MRI. J. Nucl. Med. 42, 1795-1799 (2001).
33. Brucher, B. L., Weber, W., Bauer, M., Fink, U., Avril, N., Stein, H. J., Werner, M., Zimmerman, F., Siewert, J. R., Schwaiger, M. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann. Surg. 233, 300-309 (2001).
34. Flamen, P., Lerut, A., Van Cutsem, E., Cambier, J. P., Maes, A., De Wever, W., Peeters, M., De Leyn, P., Van Raemdonck, D., Mortelmans, L. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J. Thorac. Cardiovasc. Surg. 120,1085-1092 (2000).
35. Yeung, H. W. D., Macapinlac, H., Karpeh, M., Finn, R. D., Larson, S. M. Accuracy of FDG-PET in Gastric Cancer; Preliminary Experience. Clin. Positron Imaging 1,213-221 (1998).
36. Couper, G. W., McAteer, D., Wallis, F., Norton, M., Welch, A., Nicolson, M., Park, K. G. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br. J. Surg. 85, 1403-1406 (1998).
37. Abdel-Nabi, H., Doerr, R. J., Lamonica, D. M., Cronin, V. R., Galantowicz, P. J., Carbone, G. M., Spaulding, M. B. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiolog. 206, 755-760 (1998).
38. Huebner, R. H., Park, K. C., Shepherd, J. E., Schwimmer, J., Czemin, J., Phelps, M. E., Gambhir, S. S. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J. Nucl. Med. 41, 1177-1189 (2000).
39. Ruers, T. J., Langenhoff, B. S., Neeleman, N., Jager, G. J., Strijk, S., Wobbes, T., Corstens, F. H., Oyen, W. J. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J. Clin. Oncol. 20, 388-395 (2002).
40. Delbeke, D., Martin, W. H., Sandler, M. P., Chapman, W. C., Wright, J. K. Jr, Pinson, C. W. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch. Surg. 133, 510-515 (1998).
41. Trojan, J., Schroeder, O., Raedle, J., Baum, R. P., Herrmann, G., Jacobi, V., Zeuzem, S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am. J. Gastroenterol. 94, 3314-3319 (1999).
42. Zimny, M., Buell, U. 18FDG-positron emission tomography in pancreatic cancer. Ann. Oncol. 10, Suppl. 4, 28-32 (1999).
43. Zimny, M., Schumpelick, V. Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions. Chirurg 72, 989-94 (2001).
44. Frohlich, A., Diederichs, C. G., Staib, L., Vogel, J., Beger, H. G., Reske, S. N. Detection of liver metastases from pancreatic cancer using FDG PET. J. Nucl. Med. 40, 250-255 (1999).
45. Ramdave, S., Thomas, G. W., Berlangieri, S. U., Bolton, D. M., Davis, I., Danguy, H. T., Macgregor, D., Scott, A. M. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J. Urol. 166, 825-30 (2001).
46. Shulkin, B. L., Chang, E., Strouse, P. J., Bloom, D. A., Hutchinson, R. J. PET FDG studies of Wilms tumors. J. Pediatr. Hematol. Oncol. 19, 334-338 (1997).
47. Fenchel, S., Grab, D., Nuessle, K., Kotzerke, J., Rieber, A., Kreienberg, R., Brambs, H. J., Reske, S. N. A symptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 223, 780-788 (2002).
48. Hubner, K. F., McDonald, T. W., Niethammer, J. G., Smith, G. T., Gould, H. R., Buonocore, E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol. Oncol. 51, 197-204 (1993).
49. Cho, S. M., Ha, H. K., Byun, J. Y., Lee, J. M., Kim, C. J., Nam-Koong, S. E., Lee, J. M. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. Am. J. Roentgenol. 179, 391-395 (2002). Reinhardt, M. J., Ehritt-Braun, C., Vogelgesang, D., Ihling, C.,
50. Hogerle, S., Mix, M., Moser, E., Krause, T. M. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 218, 776-782 (2001)
51. Narayan, K., Hicks, R. J., Jobling, T., Bernshaw, D., McKenzie, A. F. A comparison of MRI and PET scanning in surgically staged locoregionally advanced cervical cancer: potential impact on treatment. Int. J. Gynecol. Cancer 11, 263-271 (2001)
52. Umesaki, N., Tanaka, T., Miyama, M., Kawamura, N., Ogita, S., Kawabe, J., Okamura, T., Koyama, K., Ochi, H. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol. Oncol. 80, 372-377 (2001).
53. Belhocine, T., De Barsy, C., Hustinx, R., Willems-Foidart, J. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur. J. Nucl. Med. Mol. Imaging 29, 11321139 (2002b).
54. Cremerius, U., Wildberger, J. E., Borchers, H., Zimny, M., Jakse, G., Gunther, R. W., Buell, U. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? - Results of a study in 50 patients. Urology 54, 900-904 (1999).
55. Albers, P., Bender, H., Yilmaz, H., Schoeneich, G., Biersack, H. J., Mueller, S. C. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 53, 808-811 (1999).
56. Spermon, J. R., De Geus-Oei, L. F., Kiemeney, L. A., Witjes, J. A., Oyen, W. J. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int. 89, 549-556 (2002).
57. Effert, P. J., Bares, R., Handt, S., Wolff, J. M., Bull, U., Jakse, G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J. Urol. 155, 994-998 (1996).
58. Oyama, N., Akino, H., Suzuki, Y., Kanamaru, H., Sadato, N., Yonekura, Y., Okada, K. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn. J. Clin. Oncol. 29, 623-629 (1999).
59. Oyama, N., Akino, H., Suzuki, Y., Kanamaru, H., Ishida, H., Tanase, K., Sadato, N., Yonekura, Y., Okada, K. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl. Med. Commun. 22, 963-969 (2001).
60. Yeh, S. Detection of Bony metastases. Nuc. Med Biol. 23, 693-697 (1996).
61. Lucas, J. D. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J. Bone Joint Surg. Br. 80, 441-447 (1998).
62. Nieweg, O. E., Pruim, J., van Ginkel, R. J., Hoekstra, H. J., Paans, A. M., Molenaar, W. M., Koops, H. S., Vaalburg, W. Fluorine-18fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J. Nucl. Med. 37, 257-261 (1996).
63. Kole, A. C., Nieweg, O. E., van Ginkel, R. J., Pruim, J., Hoekstra, H. J., Paans, A. M., Vaalburg, W., Koops, H. S. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. Ann. Surg. Oncol. 4, 57-63 (1997).
64. Dimitrakopoulou-Strauss, A., Strauss, L. G., Schwarzbach, M., Burger, C., Heichel, T., Willeke, F., Mechtersheimer, G., Lehnert, T. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J. Nucl. Med. 42, 713-720 (2001).
65. Aoki, J., Watanabe, H., Shinozaki, T., Takagishi, K., Ishijima, H., Oya, N., Sato, N., Inoue, T., Endo, K. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiolog. 219, 774-777 (2001).
66. Dimitrakopoulou-Strauss, A., Strauss, L. G., Heichel, T., Wu, H., Burger, C., Bernd, L., Ewerbeck, V. The role of quantitative (18)FFDG PET studies for the differentiation of malignant and benign bone lesions. J. Nucl. Med. 43, 510-518 (2002).
67. Franzius, C., Sciuk, J., Daldrup-Link, H. E., Jurgens, H., Schober, O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur. J. Nucl. Med. 27, 1305-11(2000).
68. Daldrup-Link, H. E., Franzius, C., Link, T. M., Laukamp, D., Sciuk, J., Jurgens, H., Schober, O., Rummeny, E. J. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. Am. J. Roentgenol. 177, 229-236 (2001).
69. Franzius, C., Daldrup-Link, H. E., Wagner-Bohn, A., Sciuk, J., Heindel, W. L., Jurgens, H., Schober, O. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann. Oncol. 13, 157-60 (2002).
70. Hawkins, D. S., Rajendran, J. G., Conrad, E. U. III, Bruckner, J. D., Eary, J. F. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 94, 3277-3284 (2002).
71. Schirrmeister, H., Bommer, M., Buck, A. K., Muller, S., Messer, P., Bunjes, D., Dohner, H., Bergmann, L., Reske, S. N. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur. J. Nucl. Med. Mol. Imaging 29, 361-366 (March 2002).
72. Hoegerle, S., Altehoefer, C., Ghanem, N., Koehler, G., Waller, C. F, Scheruebl, H., Moser, E., Nitzsche, E., Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 220, 373-80 (2001).
73. Le Rest, C., Bomanji, J. B., Costa, D. C., Townsend, C. E., Visvikis, D., Ell, P. J. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur. J. Nucl. Med. 28, 478-482 (2001).
74. Shulkin, B. L., Thompson, N. W., Shapiro, B., Francis, I. R., Sisson, J. C. Pheochromocytomas: Imaging with 2[Fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212, 35-41 (1999).
75. 18F-FDG PET Detection of Lymph Node Metastases in Medullary Thyroid Carcinoma. J. Nucl. Med. 43, 66-71 (2002).
76. Shulkin, B. L., Hutchinson, R. J., Castle, V. P., Yanik, G. A., Shapiro, B., Sisson, J. C. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodoben-zylguanidine scintigraphy. Radiology 199, 743-50 (1996).
77. Kushner, B. H., Yeung, H. W., Larson, S. M., Kramer, K., Cheung, N. K. Extending positron emission tomography scan utility to highrisk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J. Clin. Oncol. 19, 3397-405 (2001).
78. Acland, K. M., O'Doherty, M. J., Russell-Jones, R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J. Am. Acad. Dermatol. 42, 606-611 (2000).
79. Belhocine, T., Pierard, G., De Labrassinne, M., Lahaye, T., Rigo, P. Staging of Regional Nodes in AJCC Stage I and II Melanoma: (18)FDG PET Imaging versus Sentinel Node Detection. Oncologist 7, 271-278 (2002a)
80. Kurhanewicz, J., Vigneron, D. B., Hricak, H., Parivar, F., Nelson, S. J., Shinohara, K., Carroll, P. R. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 200, 489-496 (1996).
81. Hara, T., Kosaka, N., Kishi, H. PET imaging of prostate cancer using carbon-11-choline. J. Nucl. Med. 39, 990-995 (1998).
82. Hara, T., Inagaki, K., Kosaka, N., Morita, T. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11 C-choline PET. J. Nucl. Med. 41, 1507-1513 (2000).
83. Hara, T., Kosaka, N., Shinoura, N., Kondo, T. PET imaging of brain tumor with [methyl-11C]choline. J. Nucl. Med. 38, 842-847 (1997).
84. Kotzerke, J., Prang, J., Neumaier, B., Volkmer, B., Guhlmann, A., Kleinschmidt, K., Hautmann, R., Reske, S. N. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur. J. Nuc. Med. 27, 1415-1419 (2000).
85. Shreve, P., Chiao, P. C., Humes, H. D., Schwaiger, M., Gross, M. D. Carbon-11-acetate PET imaging in renal disease. J. Nucl. Med. 36, 1595-1601 (1995).
86. Oyama, N., Akino, H., Kanamaru, H., Suzuki, Y., Muramoto, S., Yonekura, Y., Sadato, N., Yamamoto, K., Okada, K. 11C-Acetate PET Imaging of Prostate Cancer. J. Nucl. Med. 43, 181-186 (2002).
87. 18F-Labeled Choline Analogs as Oncologic PET Tracers. J. Nuc. Med 42, 1805-1814 (2001).
88. 18F-Fluoroethylcholine for Cancer Imaging with PET: Synthesis, Biochemistry, and Prostate Cancer Imaging. J. Nucl. Med. 43, 187-199 (2002).
89. Laverman, P., Boerman, O. C., Corstens, F. H. M., Oyen, W. J. G. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J. Nuc. Med. 29, 681-690 (2002).
90. Di Chiro, G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol. 22, 360-371 (1987).
91. 11C-Methionine PET Scans in Patients with Newly Progressive Metastatic Prostate. Cancer J. Nucl. Med. 43, 46-55 (2002).
92. Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H.-J., Stayanoff, J. C., Lawhom-Crews, J. M., Obradovich, J. E., Muzik, O., Mangner, T. J. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Medicine 4, 1334-1336 (1998).
93. Buck, A. K., Schirrmeister, H., Hetzel, M., Von Der Heide, M., Halter, G., Glatting, G., Mattfeldt, T., Liewald, F., Reske, S. N., Neumaier, B. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Research 62, 3331-3334 (2002).
94. 18F]Fluoroerythronitroimidazole PET. J. Nucl. Med. 42,1643-1652 (2001).
95. Rasey, J. S., Koh, W. J., Evans, M. L., Peterson, L. M., Lewellen, T. K., Graham, M. M., Krohn, K. A. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 36, 417-428. (1996).
96. Warner, R. R., O'dorisio, T. M. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin Nucl Med. 32, 79-83. (2002).
97. MacLaren, D. C., Toyokuni, T., Cherry, S. R., Barrio, J. R., Phelps, M. E., Herschman, H. R., Gambhir, S. S. PET Imaging of Transgene Expression. Biol. Psychiatry 48, 337-348 (2000).